JP2017517512A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517512A5
JP2017517512A5 JP2016569375A JP2016569375A JP2017517512A5 JP 2017517512 A5 JP2017517512 A5 JP 2017517512A5 JP 2016569375 A JP2016569375 A JP 2016569375A JP 2016569375 A JP2016569375 A JP 2016569375A JP 2017517512 A5 JP2017517512 A5 JP 2017517512A5
Authority
JP
Japan
Prior art keywords
halo
optionally substituted
group
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016569375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032091 external-priority patent/WO2015183709A1/en
Publication of JP2017517512A publication Critical patent/JP2017517512A/ja
Publication of JP2017517512A5 publication Critical patent/JP2017517512A5/ja
Pending legal-status Critical Current

Links

JP2016569375A 2014-05-28 2015-05-22 第xia因子インヒビター Pending JP2017517512A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003693P 2014-05-28 2014-05-28
US62/003,693 2014-05-28
PCT/US2015/032091 WO2015183709A1 (en) 2014-05-28 2015-05-22 Factor xia inhibitors

Publications (2)

Publication Number Publication Date
JP2017517512A JP2017517512A (ja) 2017-06-29
JP2017517512A5 true JP2017517512A5 (enExample) 2018-08-02

Family

ID=54699606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569375A Pending JP2017517512A (ja) 2014-05-28 2015-05-22 第xia因子インヒビター

Country Status (10)

Country Link
US (1) US9783530B2 (enExample)
EP (1) EP3148542B1 (enExample)
JP (1) JP2017517512A (enExample)
KR (1) KR20170005871A (enExample)
CN (1) CN106413710A (enExample)
AU (1) AU2015267305A1 (enExample)
CA (1) CA2947987A1 (enExample)
MX (1) MX2016015484A (enExample)
RU (1) RU2016150410A (enExample)
WO (1) WO2015183709A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
EP3180325B1 (en) * 2014-07-28 2019-03-20 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
MX2017009445A (es) 2015-01-20 2017-11-08 Merck Sharp & Dohme Inhibidores del factor xia.
US10472344B2 (en) 2015-12-02 2019-11-12 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2018039094A1 (en) 2016-08-22 2018-03-01 Merck Sharp & Dohme Corp. Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN111763171B (zh) * 2019-04-02 2023-12-22 上海美悦生物科技发展有限公司 一种FXIa凝血因子抑制剂及其药物组合物、制备方法和医药用途
MX2022003649A (es) * 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
WO2022057849A1 (zh) * 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006115652A1 (en) 2005-04-20 2006-11-02 Janssen Pharmaceutica, N.V. Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
JP2009519966A (ja) * 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な6員ヘテロ環
WO2007109459A2 (en) * 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines and pyridine n-oxides as modulators of thrombin
AU2008266228A1 (en) * 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
EP2729150B1 (en) * 2011-07-08 2016-09-14 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3180325B1 (en) 2014-07-28 2019-03-20 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Similar Documents

Publication Publication Date Title
JP2017517512A5 (enExample)
RU2016150410A (ru) Ингибиторы фактора xia
JP2018502137A5 (enExample)
JP2016516699A5 (enExample)
JP2018531954A5 (enExample)
JP2016530259A5 (enExample)
RU2017129275A (ru) ИНГИБИТОРЫ ФАКТОРА XIa
JP2017523169A5 (enExample)
JP2017504640A5 (enExample)
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
RU2018119015A (ru) ИНГИБИТОРЫ ФАКТОРА XIa
JP2016516043A5 (enExample)
JP2013537203A5 (enExample)
JP2016510326A5 (enExample)
JP2013542261A5 (enExample)
JP2016522254A5 (enExample)
JP2016513696A5 (enExample)
RU2017124150A (ru) Производное дигидроиндолизинона
EP4011871A3 (en) Processes for preparing oxathiazin-like compounds
RU2017121002A (ru) Ингибиторы CD38 и способы лечения
JP2016532647A5 (enExample)
JP2015521156A5 (enExample)
RU2017145271A (ru) Терапевтическое средство для фиброза
JP2017529357A5 (enExample)
JP2016535787A5 (enExample)